# EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Study · id `cardio:ct-nct05284747` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05284747](<https://clinicaltrials.gov/study/NCT05284747>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05284747

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 6019 participants.

## Technical summary

Registry record NCT05284747. Randomized; no masking; primary purpose treatment. Start 2022-10-26 (actual); primary completion 2027-05-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 6019 participants (enrolled count; ClinicalTrials.gov record NCT05284747, source copy `cardio:ctgov-nct05284747-2026-11-09`, retrieved 2026-11-18)
- Started: 2022-10-26 (actual) (ClinicalTrials.gov record NCT05284747, source copy `cardio:ctgov-nct05284747-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2027-05-29 (anticipated) (ClinicalTrials.gov record NCT05284747, source copy `cardio:ctgov-nct05284747-2026-11-09`, retrieved 2026-11-18)
- Completion: 2027-05-29 (anticipated) (ClinicalTrials.gov record NCT05284747, source copy `cardio:ctgov-nct05284747-2026-11-09`, retrieved 2026-11-18)
- Countries: United States; Brazil; Sweden (ClinicalTrials.gov record NCT05284747, source copy `cardio:ctgov-nct05284747-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05284747-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- Acronym: EVOLVE-MI
- Condition: Cardiovascular Disease
- Condition: Myocardial Infarction
- Condition: Stroke
- Condition: Coronary Revascularization
- Intervention (Drug): Evolocumab
- Intervention (Drug): Routine Lipid Management
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY
- Collaborator: Colorado Prevention Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)
- Registry lists this organization as a collaborator: Colorado Prevention Center (`cardio:org-colorado-prevention-center`)

## Provenance

Content hash: d0e206266deddf0edb4925383b09b4078006deb77bf48caa86d92c514d21055d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
